Country Club Bank Grows Holdings in Novo Nordisk A/S $NVO

Country Club Bank boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 83.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 49,360 shares of the company’s stock after purchasing an additional 22,394 shares during the period. Country Club Bank’s holdings in Novo Nordisk A/S were worth $2,739,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in NVO. NewSquare Capital LLC grew its holdings in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth approximately $37,000. State of Wyoming purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $38,000. Maseco LLP acquired a new position in shares of Novo Nordisk A/S in the second quarter valued at approximately $39,000. Finally, Copeland Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after purchasing an additional 186 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 2.4%

Shares of NYSE NVO opened at $47.77 on Thursday. The stock has a market capitalization of $213.28 billion, a price-to-earnings ratio of 13.89 and a beta of 0.67. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $109.04. The firm has a 50-day moving average price of $50.23 and a 200 day moving average price of $57.93. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of analyst reports. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. HSBC reaffirmed a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a research report on Tuesday, November 25th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.